Ankündigung • Jun 30
Novoray Corporation to Report First Half, 2026 Results on Aug 15, 2026 Novoray Corporation announced that they will report first half, 2026 results on Aug 15, 2026 Declared Dividend • Jun 08
Dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 10th June 2026 Payment date: 10th June 2026 Dividend yield will be 0.3%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (40% earnings payout ratio) but not adequately covered by cash flows (91% cash payout ratio). The dividend has increased by an average of 19% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 38% over the next year, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 22
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥1.21 (up from CN¥1.04 in FY 2024). Revenue: CN¥1.12b (up 16% from FY 2024). Net income: CN¥292.6m (up 16% from FY 2024). Profit margin: 26% (in line with FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Apr 21
Novoray Corporation, Annual General Meeting, May 18, 2026 Novoray Corporation, Annual General Meeting, May 18, 2026, at 14:00 China Standard Time. Location: 2F, Comprehensive Building, No. 6, Zhujiang Road, Xinpu Economic Development Zone, Haizhou District, Lianyungang, Jiangsu China Ankündigung • Mar 30
Novoray Corporation to Report Q1, 2026 Results on Apr 28, 2026 Novoray Corporation announced that they will report Q1, 2026 results on Apr 28, 2026 Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥77.18, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 137% over the past three years. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥83.30, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 25x in the Chemicals industry in China. Total returns to shareholders of 187% over the past three years. New Risk • Mar 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 17
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥1.21 (up from CN¥1.04 in FY 2024). Revenue: CN¥1.12b (up 16% from FY 2024). Net income: CN¥292.6m (up 16% from FY 2024). Profit margin: 26% (in line with FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥72.00, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 27x in the Chemicals industry in China. Total returns to shareholders of 157% over the past three years. Ankündigung • Dec 26
Novoray Corporation to Report Fiscal Year 2025 Results on Apr 22, 2026 Novoray Corporation announced that they will report fiscal year 2025 results on Apr 22, 2026 Reported Earnings • Nov 03
Third quarter 2025 earnings released: EPS: CN¥0.34 (vs CN¥0.28 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.34 (up from CN¥0.28 in 3Q 2024). Revenue: CN¥304.6m (up 22% from 3Q 2024). Net income: CN¥81.4m (up 21% from 3Q 2024). Profit margin: 27% (in line with 3Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥53.56, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 24x in the Chemicals industry in China. Total returns to shareholders of 114% over the past three years. Ankündigung • Sep 30
Novoray Corporation to Report Q3, 2025 Results on Oct 30, 2025 Novoray Corporation announced that they will report Q3, 2025 results on Oct 30, 2025 New Risk • Sep 03
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 92% Dividend yield: 0.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (92% cash payout ratio). Share price has been volatile over the past 3 months (7.5% average weekly change). Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥53.13, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 82% over the past three years. New Risk • Aug 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥59.60, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 107% over the past three years. Ankündigung • Jun 30
Novoray Corporation to Report First Half, 2025 Results on Aug 27, 2025 Novoray Corporation announced that they will report first half, 2025 results on Aug 27, 2025 Valuation Update With 7 Day Price Move • May 28
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to CN¥38.78, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 9.8% over the past three years. Declared Dividend • May 26
Dividend of CN¥0.50 announced Dividend of CN¥0.50 is the same as last year. Ex-date: 29th May 2025 Payment date: 29th May 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 17% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 82% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥47.91, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 45% over the past three years. Ankündigung • Mar 28
Novoray Corporation to Report Q1, 2025 Results on Apr 29, 2025 Novoray Corporation announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Mar 27
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: CN¥1.35 (up from CN¥0.94 in FY 2023). Revenue: CN¥960.4m (up 35% from FY 2023). Net income: CN¥251.4m (up 45% from FY 2023). Profit margin: 26% (up from 24% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 2.5%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 14% per year. Ankündigung • Mar 26
Novoray Corporation, Annual General Meeting, Apr 17, 2025 Novoray Corporation, Annual General Meeting, Apr 17, 2025, at 14:00 China Standard Time. Location: 3F, Comprehensive Building, No. 6, Zhujiang Road, Xinpu Economic Development Zone, Haizhou District, Lianyungang, Jiangsu China Ankündigung • Dec 27
Novoray Corporation to Report Fiscal Year 2024 Results on Mar 26, 2025 Novoray Corporation announced that they will report fiscal year 2024 results on Mar 26, 2025 Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥69.76, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 41% over the past three years. Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥61.88, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 46% over the past three years. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥57.50, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 43% over the past three years. Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.28 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.37 (up from CN¥0.28 in 3Q 2023). Revenue: CN¥250.4m (up 27% from 3Q 2023). Net income: CN¥67.4m (up 30% from 3Q 2023). Profit margin: 27% (in line with 3Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 12% per year. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.7% average weekly change). Ankündigung • Sep 30
Novoray Corporation to Report Q3, 2024 Results on Oct 31, 2024 Novoray Corporation announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥44.57, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 62% over the past three years. Reported Earnings • Aug 26
Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.23 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.35 (up from CN¥0.23 in 2Q 2023). Revenue: CN¥241.1m (up 43% from 2Q 2023). Net income: CN¥65.8m (up 49% from 2Q 2023). Profit margin: 27% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year. Price Target Changed • Jul 15
Price target increased by 18% to CN¥65.00 Up from CN¥55.00, the current price target is provided by 1 analyst. New target price is 21% above last closing price of CN¥53.67. Stock is down 2.3% over the past year. The company is forecast to post earnings per share of CN¥1.29 for next year compared to CN¥0.94 last year. Ankündigung • Jun 28
Novoray Corporation to Report First Half, 2024 Results on Aug 26, 2024 Novoray Corporation announced that they will report first half, 2024 results on Aug 26, 2024 Declared Dividend • Jun 03
Dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 6th June 2024 Payment date: 6th June 2024 Dividend yield will be 1.0%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by both earnings (47% earnings payout ratio) and cash flows (68% cash payout ratio). The dividend has increased by an average of 21% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 87% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.15 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.28 (up from CN¥0.15 in 1Q 2023). Revenue: CN¥202.3m (up 40% from 1Q 2023). Net income: CN¥51.7m (up 80% from 1Q 2023). Profit margin: 26% (up from 20% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Mar 29
Novoray Corporation to Report Q1, 2024 Results on Apr 26, 2024 Novoray Corporation announced that they will report Q1, 2024 results on Apr 26, 2024 Ankündigung • Mar 26
Novoray Corporation, Annual General Meeting, Apr 19, 2024 Novoray Corporation, Annual General Meeting, Apr 19, 2024, at 13:30 China Standard Time. Location: The Company's Meeting Room, Lianyungang, Jiangsu China Reported Earnings • Mar 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.94 (down from CN¥1.01 in FY 2022). Revenue: CN¥711.7m (up 7.5% from FY 2022). Net income: CN¥174.0m (down 7.6% from FY 2022). Profit margin: 24% (down from 28% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 8.5%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥35.82, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 13x in the Chemicals industry in China. Total returns to shareholders of 87% over the past three years. New Risk • Nov 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.4% average weekly change). Valuation Update With 7 Day Price Move • Nov 15
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥57.99, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 149% over the past three years. Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.21 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.28 (up from CN¥0.21 in 3Q 2022). Revenue: CN¥196.7m (up 43% from 3Q 2022). Net income: CN¥51.8m (up 33% from 3Q 2022). Profit margin: 26% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.26 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.23 (down from CN¥0.26 in 2Q 2022). Revenue: CN¥169.1m (down 2.4% from 2Q 2022). Net income: CN¥44.3m (down 11% from 2Q 2022). Profit margin: 26% (down from 29% in 2Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Aug 11
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be CN¥53.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 76% in 2 years. Earnings is forecast to grow by 94% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥51.75, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥44.12 per share. Reported Earnings • May 02
First quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.34 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.23 (down from CN¥0.34 in 1Q 2022). Revenue: CN¥145.0m (down 18% from 1Q 2022). Net income: CN¥28.7m (down 33% from 1Q 2022). Profit margin: 20% (down from 24% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 23% per year. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to CN¥87.58, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 175% over the past three years. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥67.18, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Chemicals industry in China. Total returns to shareholders of 95% over the past three years. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: CN¥1.51 (vs CN¥1.39 in FY 2021) Full year 2022 results: EPS: CN¥1.51 (up from CN¥1.39 in FY 2021). Revenue: CN¥662.0m (up 6.0% from FY 2021). Net income: CN¥188.2m (up 8.9% from FY 2021). Profit margin: 28% (in line with FY 2021). Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 16
Price target decreased to CN¥54.21 Down from CN¥81.66, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of CN¥52.00. Stock is down 19% over the past year. The company is forecast to post earnings per share of CN¥1.81 for next year compared to CN¥1.39 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Dong Hui Pan was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥73.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 7.0% over the past year. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.58 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.46 (down from CN¥0.58 in 3Q 2021). Revenue: CN¥137.2m (down 18% from 3Q 2021). Net income: CN¥39.0m (down 22% from 3Q 2021). Profit margin: 28% (down from 30% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥89.02, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 23% over the past year. Reported Earnings • Aug 16
Second quarter 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.49 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.57 (up from CN¥0.49 in 2Q 2021). Revenue: CN¥173.2m (up 16% from 2Q 2021). Net income: CN¥49.5m (up 17% from 2Q 2021). Profit margin: 29% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 39%, compared to a 42% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥97.51, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 41% over the past year. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥79.70, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 35% over the past year. Price Target Changed • Apr 27
Price target increased to CN¥118 Up from CN¥69.68, the current price target is an average from 2 analysts. New target price is 100% above last closing price of CN¥59.14. Stock is up 3.6% over the past year. The company is forecast to post earnings per share of CN¥2.99 for next year compared to CN¥2.01 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Chunyan Lu was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 04
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: EPS: CN¥2.01 (up from CN¥1.29 in FY 2020). Revenue: CN¥624.7m (up 55% from FY 2020). Net income: CN¥172.9m (up 56% from FY 2020). Profit margin: 28% (in line with FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 43%, compared to a 48% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥107, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 105% over the past year. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.33 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥166.3m (up 54% from 3Q 2020). Net income: CN¥49.8m (up 77% from 3Q 2020). Profit margin: 30% (up from 26% in 3Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.29 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥149.6m (up 49% from 2Q 2020). Net income: CN¥42.4m (up 70% from 2Q 2020). Profit margin: 28% (up from 25% in 2Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Aug 25
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥77.89, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 40% over the past year. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥74.43, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 16% over the past year. Price Target Changed • Apr 28
Price target increased to CN¥69.68 Up from CN¥64.45, the current price target is an average from 2 analysts. New target price is 22% above last closing price of CN¥57.11. Stock is up 14% over the past year. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.21 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥139.4m (up 99% from 1Q 2020). Net income: CN¥36.7m (up 106% from 1Q 2020). Profit margin: 26% (in line with 1Q 2020). Valuation Update With 7 Day Price Move • Feb 26
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥53.20, the stock is trading at a trailing P/E ratio of 47.7x, up from the previous P/E ratio of 40.5x. This compares to an average P/E of 37x in the Chemicals industry in China. Total return to shareholders over the past year is a loss of 1.1%. Is New 90 Day High Low • Feb 05
New 90-day low: CN¥40.31 The company is down 25% from its price of CN¥54.00 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.50 per share. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥40.48 The company is down 24% from its price of CN¥53.29 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.41 per share. Is New 90 Day High Low • Dec 23
New 90-day low: CN¥47.02 The company is down 9.0% from its price of CN¥51.88 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.50 per share. Valuation Update With 7 Day Price Move • Nov 16
Market pulls back on stock over the past week After last week's 15% share price decline to CN¥47.12, the stock is trading at a trailing P/E ratio of 42.3x, down from the previous P/E ratio of 49.9x. This compares to an average P/E of 39x in the Chemicals industry in China. Total returns to shareholders over the past year are 27%. Is New 90 Day High Low • Nov 03
New 90-day low: CN¥50.10 The company is down 25% from its price of CN¥66.52 on 05 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 3.0% over the same period. Reported Earnings • Oct 26
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥92.2m, up 32% from the prior year. Total revenue was CN¥367.2m over the last 12 months, up 22% from the prior year. Major Estimate Revision • Oct 24
Analysts lower revenue estimates to CN¥394.0m The 2020 consensus revenue estimate decreased from CN¥489.0m. Earning per share (EPS) estimate was also lowered from CN¥1.40 to CN¥1.14 for the same period. Net income is expected to grow by 38% next year compared to 42% growth forecast for the Chemicals industry in China. The consensus price target was lowered from CN¥79.55 to CN¥69.75. Share price is up 1.8% to CN¥53.10 over the past week. Ankündigung • Oct 19
Novoray Corporation to Report Q3, 2020 Results on Oct 22, 2020 Novoray Corporation announced that they will report Q3, 2020 results on Oct 22, 2020 Is New 90 Day High Low • Sep 24
New 90-day low: CN¥51.88 The company is down 20% from its price of CN¥64.56 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.